Literature DB >> 8813128

Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.

K Hemminki1, H Rajaniemi, B Lindahl, B Moberger.   

Abstract

Tamoxifen-induced DNA adducts were analyzed with the (32)P-postlabeling method using high-performance liquid chromatography (HPLC)-radioactivity detection from endometrial tissue of breast cancer patients and controls. Liver DNA from tamoxifen-treated rats was used as a positive standard. In blind analysis, five of the seven samples from tamoxifen-treated patients showed DNA adducts; none of the five controls were positive. The identity of the tamoxifen adduct was confirmed by using different chromatographic systems, isolating the HPLC fractions and running them on TLC, with or without spiked rat liver samples. The level of adducts in the treated patients was 2.7 adducts/10(9) nucleotides in the HPLC analysis.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8813128

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  16 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).

Authors:  Edwin J Squirewell; Xiaoyan Qin; Michael W Duffel
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

3.  Therapeutic potential of riboflavin, niacin and ascorbic acid on carbohydrate metabolizing enzymes in secondary endometrial carcinoma bearing rats.

Authors:  Sengodan Sundravel; Palanivel Shanthi; Panchanadham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2006-05-12       Impact factor: 3.396

4.  The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

Authors:  Marian Y Williams-Brown; Sana M Salih; Xia Xu; Timothy D Veenstra; Muhammad Saeed; Shaleen K Theiler; Concepcion R Diaz-Arrastia; Salama A Salama
Journal:  J Steroid Biochem Mol Biol       Date:  2011-05-10       Impact factor: 4.292

5.  Tamoxifen-DNA adduct formation in monkey and human reproductive organs.

Authors:  Elena E Hernandez-Ramon; Nicole A Sandoval; Kaarthik John; J Mark Cline; Charles E Wood; Ruth A Woodward; Miriam C Poirier
Journal:  Carcinogenesis       Date:  2014-02-05       Impact factor: 4.944

Review 6.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 7.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study.

Authors:  Ju Liu; Qian Li; Xiaofeng Yang; Richard B van Breemen; Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2005-09       Impact factor: 3.739

9.  Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.

Authors:  F De Matteis; I N White; L L Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

10.  Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene.

Authors:  Hong Liu; Zhihui Qin; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2007-07-13       Impact factor: 3.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.